Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Aurelio Hernández-Laín
Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Molecular Cancer Therapeutics
Cancer Research
Oncology
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Clinical Cancer Research
Cancer Research
Oncology
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression
Molecular Cancer Therapeutics
Cancer Research
Oncology
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma
Oncotarget
Oncology
YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
EGFR Signaling in the HGG-02 Glioblastoma Cell Line With an Unusual Loss of EGFR Gene Copy
Oncology Reports
Medicine
Cancer Research
Oncology
